Animas closes $10m purchase of Cygnus:
This article was originally published in Clinica
West Chester, Pennsylvania insulin infusion pump maker Animas has completed its asset purchase from Cygnus. The $10m cash deal, which was announced in December 2004, brings Animas electrochemical sensor continuous blood glucose monitoring technology, which Cygnus had commercialised as the GlucoWatch Biographer device. This product had a tendency to cause skin irritation. After the breakdown of a distribution deal with Sankyo, Cygnus shareholders agreed to the company's dissolution. Animas intends to replace GlucoWatch's reverse electro-iontophoresis procedure for extracting glucose molecules with micro-needle technology it recently exclusively licensed from Debiotech.